Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists
about
Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligandsCB2 receptor-mediated migration of immune cells: it can go either wayAM-251 and SR144528 are acyl CoA:cholesterol acyltransferase inhibitorsThe endocannabinoid system as an emerging target of pharmacotherapyAnalogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): development of ligands with optimized lipophilicity and binding affinityActivation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNSMinireview: From the bench, toward the clinic: therapeutic opportunities for cannabinoid receptor modulationAn optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A1 and cannabinoid CB1 receptorsΔ(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cellsAM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studiesIdentification of two distinct vasodilator pathways activated by ATP in the mesenteric bed of the ratMechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteriesCannabinoid CB1 receptor antagonists cause status epilepticus-like activity in the hippocampal neuronal culture model of acquired epilepsyIntegrated cannabinoid CB1 receptor transmission within the amygdala-prefrontal cortical pathway modulates neuronal plasticity and emotional memory encodingAnandamide improves the impaired nitric oxide-mediated neurogenic relaxation of the corpus cavernosum in diabetic rats: involvement of cannabinoid CB1 and vanilloid VR1 receptorsTRPV4 is a regulator of adipose oxidative metabolism, inflammation, and energy homeostasisSynthetic Ligands of Cannabinoid Receptors Affect Dauer Formation in the Nematode Caenorhabditis elegansInvolvement of peripheral cannabinoid and opioid receptors in β-caryophyllene-induced antinociceptionPharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation.The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsStructure elucidation of the designer drug N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-3-(4-fluorophenyl)-pyrazole-5-carboxamide and the relevance of predicted (13) C NMR shifts - a case study.delta(9)-Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells. Involvement of CB1 cannabinoid receptor and Raf-1.Functionally Optimized Neuritogenic Farinosone C Analogs: SAR-Study and Investigations on Their Mode of ActionFunctional characterization of transient receptor potential channels in mouse urothelial cells.hCB2 ligand-interaction landscape: cysteine residues critical to biarylpyrazole antagonist binding motif and receptor modulation.Cannabinoid receptor 1 blockade ameliorates albuminuria in experimental diabetic nephropathy.2012 Division of medicinal chemistry award address. Trekking the cannabinoid road: a personal perspectiveCannabinoid CB1 receptor facilitation of substance P release in the rat spinal cord, measured as neurokinin 1 receptor internalization.Pharmacological characterization of GPR55, a putative cannabinoid receptorEffects of the endogenous cannabinoid anandamide on voltage-dependent sodium and calcium channels in rat ventricular myocytesPeripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity.A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodentsBML-190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: signalling via cAMP and inositol phosphates.3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.Effects of cannabinoid receptor antagonists on maintenance and reinstatement of methamphetamine self-administration in rhesus monkeys.Cannabinoid receptors as target for treatment of osteoporosis: a tale of two therapies.Interaction between lysophosphatidic acid, prostaglandins and the endocannabinoid system during the window of implantation in the rat uterus.Ethyl 1-tert-butyl-5-phenyl-1H-pyrazole-4-carboxyl-ateEthyl 1,5-diphenyl-1H-pyrazole-4-carboxyl-ate.
P2860
Q24311776-6973AF28-F862-4024-91AE-4E960D44377AQ24643591-8DD2E910-6E2F-45FF-AAB1-B6FC1EDF1F5AQ24647198-CBB6AE48-0BD4-4BD1-960F-D1E770532BFEQ24648473-2FF407FD-7640-4010-AE53-2315527BE08BQ24650317-E6B88E29-CBDC-4683-9991-414A074A92F1Q24683100-05D22180-79F9-4CAD-82BD-4B188B6724BAQ26829111-40D540C0-E88E-4496-8C65-E247BCF22BC5Q28185158-33B3B68C-7135-4422-8E9A-C5BEA852F1FAQ28238141-89304FAF-1C87-4736-A2CC-D7AD95143967Q28270589-4F65CBB9-9082-49E1-8014-EB3E9A5DE97EQ28343908-8DB4668A-2144-45BF-9AD5-0E1DCD8E1DEAQ28362103-13DCA9B2-687A-4A60-904F-3BB52CAFFFF6Q28573365-55A6298F-FA76-40E1-8C3F-E675CE74528CQ28576418-EE82135F-A0BC-4F95-BB09-4BBE4385A244Q28581593-DAFA784F-C6A5-4F2D-86DD-D1D9996E4A28Q28586703-2A860B84-D34F-422C-B1E2-7137A14B432BQ28829473-864A4019-31B6-4383-91D6-274B3CF4914FQ29395820-70132B6A-363B-40E6-89C9-773DDA7D3062Q30366778-D0874E74-83A7-457E-8A39-9C34385C5275Q30373403-595536CB-5029-4148-818E-03CAA960B47AQ30486707-AD316BAB-0C46-4542-AF28-92530016D341Q30487997-64636B70-416D-4E32-9D40-B876D10D0B92Q31896948-47070DD0-373B-4550-B33C-97ED4CA4B28BQ33636160-911701F3-6F90-46E4-A6AB-D0D72971281BQ33727822-9D24A893-6CB4-4E6F-B2E5-82A73EB75891Q33733994-5D9441C6-75E3-42DF-ADA1-1FE7AF8B255CQ33750632-247045C7-3771-4CDE-8A17-E32AAAE791A3Q33781776-E3BC7111-8F5A-43C4-9E6F-762354B50E60Q33803774-A0A6974E-8F0B-4CA9-A770-C893ECD19C88Q33869340-A8F27742-AD15-42E1-BF20-529A34C71C22Q33929785-77AE618A-B0D1-4739-BBF3-98BB4DFB8133Q34028741-1F3D775F-1438-4A70-8D7A-ECBC2AB728B3Q34140803-42D8AF63-F33B-4E6E-A496-D2890676F487Q34177133-297C0371-AE79-4B95-9462-590154676F7AQ34232856-D8F854A9-502E-4A78-AE4A-388B5177B4F1Q34280424-D33B890E-5770-4221-895F-8B8AFD6E8166Q34402180-6BE6AE1F-D68B-4A9F-8505-2CFDF82C0DA7Q34430743-FAC20DF2-3055-4031-984C-03785995CFFEQ34431112-9B787209-7F8C-489F-B396-79E389052EA7Q34431683-AD2EF67E-7C5A-4D3B-AE17-64B314AA7FE6
P2860
Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Structure-activity relationshi ...... nnabinoid receptor antagonists
@ast
Structure-activity relationshi ...... nnabinoid receptor antagonists
@en
Structure-activity relationshi ...... nnabinoid receptor antagonists
@nl
type
label
Structure-activity relationshi ...... nnabinoid receptor antagonists
@ast
Structure-activity relationshi ...... nnabinoid receptor antagonists
@en
Structure-activity relationshi ...... nnabinoid receptor antagonists
@nl
prefLabel
Structure-activity relationshi ...... nnabinoid receptor antagonists
@ast
Structure-activity relationshi ...... nnabinoid receptor antagonists
@en
Structure-activity relationshi ...... nnabinoid receptor antagonists
@nl
P2093
P921
P3181
P356
P1476
Structure-activity relationshi ...... nnabinoid receptor antagonists
@en
P2093
D McCallion
S R Fernando
P304
P3181
P356
10.1021/JM980363Y
P407
P577
1999-02-25T00:00:00Z